Ocular Therapeutix at a Crossroads Ahead of March Investor Tour

BEDFORD, Mass. – February 24, 2026 – By Nancy Torres

Ocular Therapeutix, Inc. is gearing up for a pivotal March, with executives embarking on a five-conference tour to engage the financial community. But this is no ordinary roadshow. The biopharmaceutical company stands at a critical juncture, balancing the immense promise of its late-stage retinal disease pipeline against challenging commercial realities and mounting R&D expenditures. Investors will be listening intently as CEO Pravin U. Dugel, MD, takes the stage, with the company's future valuation hanging in the balance.

A High-Stakes Roadshow

The company announced it will participate in a series of high-profile investor conferences, including the TD Cowen Health Care Conference, Jefferies Biotech on the Beach Summit, and the Barclays Global Healthcare Conference. Dr. Dugel is scheduled to lead fireside chats at three of these events, offering a direct channel to address the questions weighing on investors' minds.

This intense schedule of engagement comes just as Ocular is poised to release the most important clinical data in its history. The timing is no coincidence. The presentations offer a crucial platform to frame the narrative around its lead candidate, AXPAXLI, and reassure stakeholders about the company’s long-term strategy. Market sentiment has been cautious, with Ocular’s stock reacting negatively to past financial updates. Analysts are keenly watching for clarity on clinical progress, commercial performance, and capital allocation. The March tour is the company's opportunity to seize control of that narrative ahead of what could be a transformative period.

The Billion-Dollar Question: AXPAXLI's Superiority Play

At the heart of investor anticipation is AXPAXLI (OTX-TKI), an investigational axitinib intravitreal hydrogel designed to treat major retinal diseases. The company's entire strategy appears to hinge on its success, particularly in the multi-billion dollar market for wet age-related macular degeneration (wet AMD).

Ocular is running two parallel Phase 3 trials for wet AMD. The most watched is the SOL-1 trial, which completed enrollment of 344 patients in December 2024. Crucially, this is a superiority trial designed to show that AXPAXLI is more effective than a single dose of aflibercept (marketed as EYLEA), a current standard of care. Topline 52-week data from SOL-1 is expected to be presented at the Macula Society Annual Meeting between February 25-28, 2026, just days before the investor tour kicks off. Positive results could make AXPAXLI the first and only therapy in its class with a superiority label, a powerful differentiator in a crowded and competitive market dominated by giants like Regeneron and Roche.

A second Phase 3 trial, SOL-R, is a larger non-inferiority study that completed enrollment of 631 subjects in December 2025. Ocular recently announced an accelerated timeline for this trial, with data now expected in the first quarter of 2027. The company’s pipeline ambitions don’t stop there; its HELIOS program is advancing AXPAXLI into Phase 3 trials for diabetic retinopathy, another major cause of blindness, with the potential for a broad superiority label across the spectrum of diabetic retinal disease.

Navigating Commercial Headwinds

While the pipeline holds future promise, the company's current commercial performance presents a more complex picture. Ocular's full-year 2025 financial results revealed a challenging environment. Total net revenue fell to $52.0 million, an 18.5% decrease from the previous year, while the company's net loss widened significantly to $265.9 million from $193.5 million in 2024.

The decline was largely driven by its sole commercial product, DEXTENZA, an FDA-approved corticosteroid implant. Despite achieving its highest-ever annual unit volume in 2025, net revenue from the product declined. The company attributed this paradox to a "significantly more challenging reimbursement environment," including the impact of Medicare reimbursement caps, rebates, and discounts that have eroded profitability per unit.

This commercial pressure is juxtaposed against a massive surge in spending. Research and development expenses skyrocketed to $197.1 million in 2025, up from $127.6 million in 2024. This increase is almost entirely due to the costs of running the large-scale Phase 3 programs for AXPAXLI. This dynamic illustrates the classic biotech balancing act: burning through cash to fund a potentially transformative pipeline, all while managing the market realities of an existing commercial product.

Pipeline Decisions and Financial Fortitude

Given the heavy investment in AXPAXLI, other parts of Ocular’s pipeline are under strategic review. The company's press release noted it is "evaluating next steps" for OTX-TIC, an investigational glaucoma treatment that has completed a Phase 2 trial. While repeat-dosing data was consistent, this language often signals a company is considering pausing, partnering, or deprioritizing a program to focus resources on its lead assets—a logical move given the capital-intensive nature of the AXPAXLI trials.

Despite the widening losses and commercial pressures, Ocular has fortified its balance sheet to weather the storm. A successful equity offering in September 2025 raised approximately $445.6 million in net proceeds. As of the end of 2025, the company reported a cash balance of $737.1 million. Management has stated this provides a cash runway into 2028, a crucial buffer that extends well beyond the anticipated data readouts for its key AXPAXLI trials.

This financial stability gives the company the flexibility to execute its ambitious clinical and regulatory plans without immediate financing pressure. For investors tuning into the March conferences, the message will be clear: Ocular has the capital to see its big bet through. The primary question now is whether the upcoming SOL-1 data will prove that the bet is ready to pay off.